Printer Friendly

FDA APPROVES SCHERING-PLOUGH'S NDA TO MARKET REBETOL.

Enzon, Inc. (NASDAQ: ENZN), Piscataway, N.J., has announced that Schering-Plough Corporation (NYSE:SGP) has reported that it has been granted marketing approval from the U.S. Food and Drug Administration (FDA) for REBETOL(R) (ribavirin, USP) Capsules as a separately marketed product for use only in combination with INTRON(R) A (interferon alfa-2b, recombinant) Injection for the treatment of chronic hepatitis C in patients with compensated liver disease previously untreated with alpha interferon or who have relapsed following alpha interferon therapy.

The safety and efficacy of REBETOL Capsules with interferons other than INTRON A have not been established.

REBETOL had been previously approved in the United States for this indication only as a component of REBETRON(TM) Combination Therapy, which contains REBETOL Capsules and INTRON A Injection in a single package. Schering-Plough has reported it will continue to market REBETRON Combination Therapy in the United States.

Schering-Plough expects REBETOL Capsules, available by prescription only, to be available nationwide sometime this fall.

In February 2001, Schering-Plough submitted a supplemental Biologics License Application (sBLA) to the FDA seeking marketing approval of PEG-INTRON for use in combination therapy with REBETOL for the treatment of chronic hepatitis C in patients not previously treated with interferon alpha who have compensated liver disease and are at least 18 years of age.

PEG-INTRON (peginterferon alfa-2b) is a longer-acting form of INTRON(R) A (interferon alfa-2b, recombinant) Injection that uses proprietary PEG technology developed by Enzon. Under the company's licensing agreement with Schering-Plough, Enzon is entitled to royalties on worldwide sales of PEG-INTRON.

Enzon is a biopharmaceutical company developing advanced therapeutics for life-threatening diseases through the application of its proprietary drug delivery and targeting technologies, PEG Modification, Pro Drug/Transport technology and Single-Chain Antigen-Binding (SCA(R)) protein technology. Three products are currently marketed which utilize Enzon's technology: PEG-INTRON marketed by Schering-Plough for hepatitis C, ONCASPAR(R) for Acute Lymphoblastic Leukemia (ALL), and ADAGEN(R) a treatment for a form of Severe Combined Immunodeficiency Disease (SCID), commonly known as the "Bubble Boy Disease." In addition to three approved products, Enzon has several products in various stages of clinical development by itself and with partners, including additional indications for PEG-INTRON with Schering-Plough. A Phase III clinical trial is being conducted for PEG-INTRON for the treatment of malignant melanoma. Enzon develops and markets products on its own and through strategic alliances, which in addition to Schering-Plough Corporation, include Alexion Pharmaceuticals, Inc., Baxter Healthcare Corporation, Bristol-Myers Squibb Company, Eli Lilly & Company, and Aventis.

For more information, visit http://www.enzon.com or call 732-980-4717.
COPYRIGHT 2001 Worldwide Videotex
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2001 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Comment:FDA APPROVES SCHERING-PLOUGH'S NDA TO MARKET REBETOL.
Publication:Biotech Business
Geographic Code:1USA
Date:Sep 1, 2001
Words:423
Previous Article:FDA CONFIRMS PRIORITY REVIEW OF LILLY'S DRUG FOR SEPSIS.
Next Article:XOMA STARTS PHASE II TRIAL OF NEUPREX IN CROHN'S DISEASE.
Topics:


Related Articles
FDA ASSIGNS PRIORITY REVIEW STATUS TO PEG-INTRON/REBETOL.
ENZON REPORTS 127% INCREASE IN 4TH QTR REVENUES.
RIBAPHARM REPORTS INCREASE IN FIRST QTR 2002 NET INCOME.
Ribapharm files patent infringement lawsuit against Hoffmann-La Roche.
Schering-Plough launches hepatitis treatment in Europe.
Schering-Plough and Biogen settle royalty payment arbitrations.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters